

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: SOL Global Investments Corp. (the "Company" or "Issuer").

Trading Symbol: SOL

Number of Outstanding Listed Securities: 54,531,349

Date: March 5, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website. This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

On February 20, 2020, the Issuer announced that Goldstream and CannCure Investments Inc. ("CannCure"), a portfolio company of Issuer, have entered into a definitive business combination agreement (the "Combination Agreement") which, subject to certain conditions and applicable shareholder and regulatory approvals, including, without limitation, approval from the Florida Department of Health, Office of Medical Marijuana Use, will result in a reverse takeover of Goldstream by CannCure (the "Proposed Transaction"). The resulting issuer from the Proposed Transaction (the "Resulting Issuer") will carry on the business of CannCure as a U.S. multi-state

cannabis company (the “MSO”). The Resulting Issuer will initially operate in the State of Florida via One Plant Florida (formerly 3 Boys Farm LLC) and in the event that its proposed acquisition of ECD Holdings Inc. (d/b/a as “Northern Emeralds”) is completed, will begin operations in the State of California. As was previously announced, Brady Cobb will step down as CEO and as a director of Issuer to lead the new MSO effective upon the closing of the Proposed Transaction. Closing of the Proposed Transaction is expected to occur in late April, 2020 or such other date as may be mutually agreed to by the parties. Under the terms of the Combination Agreement, the Proposed Transaction will be completed by way of a three-cornered amalgamation involving a wholly-owned subsidiary of Goldstream amalgamating with CannCure to form a single, wholly-owned subsidiary of the Resulting Issuer. In connection with the Proposed Transaction, Goldstream will reconstitute its board of directors and management team and change its name to “Bluma Wellness Inc.” or such other similar name as may be accepted by the relevant regulatory authorities (the “Name Change”) and the Resulting Issuer will conduct its business under the new name. As a condition to the Proposed Transaction, Goldstream will de-list from the NEX board of the TSX Venture Exchange (“TSXV”) and the Resulting Issuer will apply to list its common shares on the Canadian Securities Exchange (the “CSE”). The Proposed Transaction cannot be completed while Goldstream is listed on the NEX board of the TSXV. The Combination Agreement includes a number of other conditions, including but not limited to: the consolidation of Goldstream’s common shares on a 23.3053:1 basis (the “Consolidation”), the issuance of post-Consolidation Goldstream common shares to holders of CannCure common shares (the “CannCure Shares”) on a 1:1 basis; the continuance of Goldstream into the province of British Columbia; the entering into of lock-up agreements by certain CannCure shareholders, officers and directors; CannCure obtaining a US\$15,000,000 construction loan from an arm’s length third party lender or completing an alternative financing to ensure sufficient funding for the MSO operations following closing; the approvals of all regulatory bodies having jurisdiction in connection with the Proposed Transaction, including, without limitation, approval from the Florida Department of Health, Office of Medical Marijuana Use. An annual general and special meeting of shareholders of Goldstream will be held on April 9, 2020 to consider and approve, among other things, the de-listing of Goldstream from the NEX, the reconstitution of Goldstream’s board of directors, the Name Change and the Consolidation. Pursuant to the terms of the Combination Agreement, and in connection with the Proposed Transaction: holders of CannCure Shares will receive one (1) fully paid and non-assessable post-Consolidation Resulting Issuer share for each CannCure Share held; and all outstanding warrants, convertible debentures and other securities to purchase CannCure Shares will be exchanged on an equivalent basis for warrants, convertible debentures and other such securities to purchase common shares of the Resulting Issuer. Upon the completion of the Proposed Transaction, it is expected that holders of CannCure Shares, including those parties expected to receive CannCure Shares as partial consideration for the sale of Northern Emeralds to CannCure and the former CannCure shareholders who have received CannCure Shares in connection with the satisfaction of the Earn-Out (as described below), will hold approximately 99% of the issued and outstanding Resulting Issuer shares on a non-diluted basis. Issuer will be one of the largest shareholders of the Resulting Issuer. The entering into of the

Business Combination Agreement triggered the clause under the CannCure earn-out in accordance with the terms of the amended and restated purchase agreement dated April 8, 2019 (the "Agreement") between Issuer and the former shareholders of CannCure. Issuer transferred an aggregate of 35,151,483 CannCure Shares to the former shareholders of CannCure based on the calculation outlined in the Agreement, thereby fully satisfying the earn-out provision. Subject to applicable shareholder and CSE approval, upon completion of the Proposed Transaction, the board of directors and management of the Resulting Issuer will be comprised of the following individuals: Brady Cobb, Chief Executive Officer and Director, Michael Bondurant, President and Chief Strategy Officer, Michael Smuts, Chief Operating Officer, Chris Polaszek, Chief Legal Officer, Cody Stross, Chief Cultivation Officer and Director, Chad Moss, Chairman of the Board of Directors, Adam Wilks, Director.

On February 21, 2020 the Issuer announced that CannCure Investments Inc. ("CannCure"), a portfolio company of Issuer, has secured a USD\$15,000,000 construction loan from Advanced Flower Capital to fund the construction and development of a new, state-of-the-art, 88,327 square foot tilt-up indoor cultivation, processing and lab facility in Indiantown, Florida for CannCure's One Plant Florida (formerly 3 Boys Farm, LLC). The construction loan will be secured by a mortgage and other commercially-common security interests. Obtaining the construction loan satisfies one of the conditions under the previously announced business combination agreement between CannCure, Goldstream Minerals Inc. ("Goldstream"), and a wholly-owned subsidiary of Goldstream, that will result in the reverse takeover of Goldstream by the shareholders of CannCure (the "RTO"). The construction loan consists of a five-year USD\$15,000,000 loan, with year one interest only on the amount outstanding, future advances not to exceed USD\$20,000,000 USD in total, and an interest rate of 13.5%. The construction loan is secured by a mortgage and other commercially-common security interests and instruments.

Issuer announced that the previously announced binding letter of intent between Three Habitat Consulting HoldCo, Inc., a Delaware corporation d/b/a One Plant California and CannCure has been terminated at the mutual wishes of the parties following a re-evaluation of the transaction in light of current market conditions. The parties have since entered into a long-term license agreement whereby One Plant Florida will retain exclusive use of all One Plant intellectual property within the State of Florida.

On February 3, 2020 the Issuer disposed of 1,046,000 common shares ("Common Shares") of Frankly Inc. ("Frankly") (TSXV:TLK) through the facilities of the TSX Venture Exchange (the "Disposition"). The consideration received per Common Share under the Disposition was approximately \$0.55, for total consideration received of \$578,703. The completion of the Disposition, together with other dispositions of Common Shares by Issuer since the last early warning report of Common Shares disposed of by the Company filed on January 27, 2020 resulted in a greater than 2.0% decrease in the 11.4% Common Share holding reported in the January 27 Report. Immediately before the completion of the Disposition, issuer owned 2,989,100 Common Shares, representing approximately 9.78% of the issued and outstanding Common Shares on a non-diluted basis. Following the completion of the Disposition,

Issuer owned 1,943,100 Common Shares, representing approximately 6.36% of the issued and outstanding Common Shares on a non-diluted basis. Together with the 2,350,000 Common Share purchase warrants of Frankly currently held by Issuer, Issuer beneficially owns 13.04% of Frankly on a partially diluted basis. The completion of the Disposition led to a 3.42% decrease in the Issuer's security holding percentage of the issued and outstanding Common Shares. Issuer does not anticipate disposing of any additional shares in Frankly in the immediate term.

**2. Describe the acquisition of new customers or loss of customers.**

None noted.

**3. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

None noted.

**4. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None noted.

**5. Report on any labour disputes and resolutions of those disputes if applicable.**

None noted.

**6. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None noted.

**7. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None noted.

**8. Provide details of any securities issued and options or warrants granted.**

None noted.

**9. Provide details of any loans to or by Related Persons**

None noted.

**10. Provide details of any changes in directors, officers or committee members.**

None noted

**11. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

None noted.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: March 5, 2020.

Peter Liabotis  
Name of Director or Senior Officer  
/s/ "Peter Liabotis"  
Signature  
CFO  
Official Capacity

<b>Issuer Details</b> Name of Issuer SOL Global Investments Corp.	For Month End February 2020	Date of Report YY/MM/D 20/03/05
Issuer Address 5600-100 King St. West		
City/Province/Postal Code Toronto, ON, M5X 1C9	Issuer Fax No. (   )	Issuer Telephone No. (212) 729-9208
Contact Name Peter Liabotis	Contact Position CFO	Contact Telephone No. (212) 729-9208
Contact Email Address <a href="mailto:info@solglobal.com">info@solglobal.com</a>	Web Site Address <a href="https://solglobal.com/">https://solglobal.com/</a>	